Skip to main content

Advertisement

Table 1 Demographic, clinical and serological characteristics of lcSSc patients and healthy controls

From: Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature

  Control subjects (n = 8) All LcSSc patients (n = 15)
Age, median (range) years 53 (29–70) 62 (28–15)
Sex, N (%) female 4 (50) 12 (80)
Race, N (%) Caucasian 7 (87.5) 10 (100)
MRSS, median (range)   6 (3–10)
Disease duration from first non-Raynaud’s symptom, median (range) years   14 (2–40)
ANA primary pattern, N (%) patients Homogenous   4 (27)
Speckled   2 (13)
Centromere   6 (40)
Nucleolar   1 (7)
SSc-specific antibodies Scl-70   4 (27)
RNA pol III   0
Vasculopathy, N (%) patients Digital ulcers   6 (40)
PAH   0
Renal crisis   0
Interstitial lung disease, N (%)   4 (27)
Inflammatory arthritis, N (%)   3 (20)
Vascular therapies, N (%) patients ARB   10 (66)
Ca channel antagonist   4 (27)
Iloprost   4 (27)
PDE5 inhibitor   3 (20)
Immunosuppressive therapies, N (%) patients PDN   4 (27)
MMF   3 (20)
MTX   2 (13)
AZA   1 (7)
HCQ   3 (20)
  1. ANA antinuclear antibodies, SSc systemic sclerosis, MRSS modified Rodnan skin score, PAH pulmonary arterial hypertension, ARB angiotensin receptor blocker, PDE cGMP-regulated phosphodiesterase, MTX methotrexate, HCQ hydroxychloroquine, PDN prednisolone, AZA azathioprine